logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11400149 B1

PDFFull Text
Date of Patent:
Aug. 02, 2022

Filed:

Dec. 11, 2018

Ebola virus and marburg virus glycoprotein mucin-like domain replacement expression system used as new vaccine approaches

Applicant:

University of Manitoba, Winnipeg, CA;

Inventors:

Xiaojian Yao, Winnipeg, CA;

Zhujun Ao, Winnipeg, CA;

Gary Kobinger, Winnipeg, CA;

Assignee:

University of Manitoba, Winnipeg, CA;

Attorneys:

Michael R Williams

Ryan W Dupuis

Ade & Company Inc.

Primary Examiner:

Barry A Chestnut

Int. Cl.
CPC ...
A61K 39/12 (2006.01); A61K 39/00 (2006.01); C12N 7/00 (2006.01); C07K 14/005 (2006.01); A61K 39/145 (2006.01); A61K 39/385 (2006.01); C12N 15/62 (2006.01);
U.S. Cl.
CPC ...
A61K 39/12 (2013.01); A61K 39/385 (2013.01); C07K 14/005 (2013.01); C12N 15/62 (2013.01); A61K 2039/5258 (2013.01); A61K 2039/6075 (2013.01); C12N 2740/16023 (2013.01); C12N 2740/16034 (2013.01); C12N 2740/16134 (2013.01); C12N 2760/14123 (2013.01); C12N 2760/14134 (2013.01);
Abstract

We have developed a series of Ebola vims envelope glycoprotein (EboGP)-based chimeric fusion proteins that are still able to maintain an efficient EboGP-mediated virus entry in various cell types including human antigen-presenting cells (APCs) while presenting large viral polypeptides, such as HIV Env v3-v5 domain (as large as 241 aa), at the apex and the sides of each EboGP monomer to elicit robust host immune responses. This invention demonstrates the feasibility of an EboGP-based chimeric fusion technology as a novel vaccine approach against different microbial pathogens, including that in human and animals, and against cancers.

Find Patent Forward Citations

Yao, Xiaojian. (2022). Ebola virus and marburg virus glycoprotein mucin-like domain replacement expression system used as new vaccine approaches (U.S. Patent No. 11400149). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/11400149

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…